RB1CC1 Activates RB1 Pathway and Inhibits Proliferation and Cologenic Survival in Human Cancer

Tokuhiro Chano1, Kaichiro Ikebuchi1,–2, Yasuko Ochi1,–2, Hitosuke Tameno1,2, Yasuhiko Tomita3, Yufen Jin3, Hideo Inaji4, Makoto Ishitobi4, Koji Teramoto5, Ichiro Nishimura1, Kahori Minami1, Hirokazu Inoue6, Takahiro Isono7, Masao Saitoh8, Taketoshi Shimada2, Yasuo Hisa2, Hidetoshi Okabe1

1 Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Otsu, Japan, 2 Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefecture University of Medicine, Kyoto, Japan, 3 Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, 4 Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, 5 Department of Thoracic Surgery, Shiga University of Medical Science, Otsu, Japan, 6 Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, 7 Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefecture University of Medicine, Kyoto, Japan

Abstract

RB1-inducible coiled-coil 1 (RB1CC1, also known as FIP200) plays a role in the enhancement of the RB1 pathway through the direct binding to a GC-rich region 201bp upstream (from the initiation ATG) of the RB1 promoter. Here, we identified hSNF5 and p53 as the binding partners of RB1CC1 by immunoprecipitation and immunofluorescence assays. Interaction between these molecules and the RB1 pathway was analyzed by the assays of chromatin immunoprecipitation, luciferase-reporter, reverse transcription-polymerase chain reaction and immunoblot. The tumor growth suppression by RB1CC1 was evaluated by flow cytometry or by a cell growth assay. The nuclear RB1CC1 complex involving hSNF5 and/or p53 activated transcription of RB1, p16 and p21, and suppressed tumor cell growth. Furthermore, nuclear RB1CC1 expression significantly correlated with those of RB1 and p16 in breast cancer tissue in vivo, and the Ki-67 proliferation index was dependent on p53 as well as RB1CC1. The present study indicates that RB1CC1 together with hSNF5 and/or p53 enhances the RB1 pathway through transcriptional activation of RB1, p16 and p21. Evaluation of RB1CC1 expression combined with RB1 and p53 status is expected to provide useful information in clinical practice and future therapeutic strategies in breast cancer.

Introduction

The retinoblastoma tumor suppressor protein (RB1) regulates G1/S-cell cycle progression and is a critical mediator of antiproliferative signaling. Although phosphorylation plays an important role in the functional regulation of RB1, the transcriptional regulation of RB1 is much less known [1]. RB1-inducible coiled-coil 1 (RB1CC1: the symbol used here, which is approved by the Human Genome Organization [HUGO] Gene Nomenclature Committee; it is also known as FIP200, focal adhesion kinase family-interacting protein of 200 kDa) was identified as an RB1 pathway regulator that in particular enhances RB1 transcription [2,3]. Recently, we have demonstrated that nuclear RB1CC1 binds to a GC-rich region 201bp upstream (from the initiation ATG) of the RB1 promoter and activates the expression of RB1 [4]. A genetic rearrangement of RB1CC1 has also been suggested to be involved in the tumorigenesis of breast cancer [3,5]. Interestingly, it has been reported that RB1CC1 binds and stabilizes p53 [6], suggesting that RB1CC1 might be an important mediator connecting the RB1 and p53 pathways. Our present study investigates the mechanism of RB1CC1 enhancement of the RB1 pathway. RB1CC1 forms a complex with p53 and/or hSNF5, a chromatin-remodeling factor, in cell nuclei, and activates the transcription of RB1, p16 and p21. In addition, nuclear RB1CC1 significantly correlates RB1 and p16 expression in breast cancer tissue in vivo.

Results

RB1CC1 forms a complex with hSNF5 and/or p53

We initially attempted to identify RB1CC1-binding proteins in MCF-7 breast cancer cells by an immunoprecipitation assay followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A chromatin remodeling factor, hSNF5 (also known as BAFA47 or IN11) was co-immunoprecipitated with RB1CC1 (Fig. 1A). The pull-down assay using RB1CC1 deletion-mutants revealed that the C-terminal region of RB1CC1 (aa 1364-1594) was required for the interaction with hSNF5 (Fig. 1B and C). The N-terminus of RB1CC1 also interacts with p53 [6], so we considered that RB1CC1 might form a complex with hSNF5 and/or p53 to inhibit tumor growth. The complex formation between RB1CC1, hSNF5 and p53 was evaluated by immunoprecipitation and immunofluorescence assays. RB1CC1, hSNF5 and p53 were co-immunoprecipitated with two kinds of antibodies
Figure 1. RB1CC1 forms a complex with hSNF5 and/or p53. (A) MCF-7 cell lysates were immunoprecipitated (IP) with anti-RB1CC1 antibody and analyzed by SDS-PAGE followed by silver staining. The molecule that co-immunoprecipitated with RB1CC1 was identified as hSNF5 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (B) Flag-RB1CC1 and HA-hSNF5 were co-transfected into HEK293 cells. Lysates were immunoprecipitated with anti-Flag or anti-HA antibody, and analyzed by immunoblots as indicated. Arrowheads indicate the co-immunoprecipitated signals. (C) HEK293 cells were transfected with both HA-hSNF5 wildtype (full) and Flag-RB1CC1 variants; wildtype (wt), dccA, dccB, dlZ, LZC, dCC and Fcc. Schematic diagrams of RB1CC1wt and mutants are also indicated on the left side. The rectangle shows the binding site for hSNF5, and the broken rectangle indicates that for p53. Cell lysates were immunoprecipitated with anti-HA antibody and immunoblotted as indicated. (D) MCF-7 lysates were immunoprecipitated with two kinds of anti-RB1CC1 antibody and analyzed by immunoblots. (E) RB1CC1 (green), hSNF5 (red), p53 (blue) and the merged image in HeLa cells. Each protein is immunofluorescently labeled by Alexa 488, 594 or 350 respectively. Scale bar, 50 µm. (F) RB1CC1 (green), DAPI and the merged image in HeLa cells. RB1CC1 is immuno-labeled by Alexa 488, and DAPI is displayed with blue fluorescence in cell nuclei. Scale bar, 50 µm.

doi:10.1371/journal.pone.0011404.g001
recognizing different sites (aa. 25–271 and 549–817) of RB1CC1; the composition of each of the precipitates is different, probably due to the preferable fractions to each antibody (Fig. 1D). RB1CC1-1 and -2 antibodies have tended to bind more preferably to the nuclear and cytoplasmic fractions, respectively, hSNF5 and abundantly nuclear p53 (that might be more phosphorylated and slowly mobilized in PAGE) might be preferably co-precipitated with the complex between nuclear RB1CC1 and RB1CC1-1 antibody. Reciprocally, RB1CC1-2 antibody might dominantly bind to abundant cytoplasmic RB1CC1 as well as hSNF5 and a few of p53 in cytoplasm. RB1CC1, hSNF5 and p53 were co-localized in cell nuclei with the exception of nucleoli (Fig. 1E and F; Fig S1). The data indicated that RB1CC1 forms a complex with hSNF5 and/or p53 mainly in cell nuclei.

RB1CC1 binds to and activates the promoters of RB1, p16 and p21, cooperating with p53 and/or hSNF5

RB1CC1 [2,4,6] and hSNF5 [7,8,9,10] enhance transcription of the molecules involved in the RB1 pathway, so we examined whether RB1CC1, hSNF5 and p53 bind to the promoter regions of RB1, p16 and p21. Chromatin immunoprecipitation (ChIP) assays using antibodies against RB1CC1, hSNF5 and p53 indicated that promoter fragments of RB1, p16 and p21, which were amplified from HeLa cell chromatin, were precipitated by each antibody (Fig 2A), suggesting that the molecules are recruited to the promoter regions of the RB1 pathway. The involvement of these three molecules in the expression of RB1, p16 and p21 were validated by introducing sh-RNA for RB1CC1 (sh-RB1CC1), hSNF5 (sh-hSNF5) and p53 (sh-p53) into HeLa cells. The knockdown effects on RB1CC1, hSNF5, p53, p21 and RB1 mRNA expression were analyzed by semi-quantitative RT-PCR. sh-RB1CC1 and sh-hSNF5 decreased mRNA levels of RB1, p16 and p21, whereas sh-p53 decreased only p21 mRNA (Fig. 2B). In other words, RB1CC1 and hSNF5 are required to maintain transcriptions of RB1, p16 and p21, whereas p53 is specifically required for transcription of p21. RB1CC1 significantly activated the promoters of RB1, p16 and p21 (Fig. 2C), and the knockdown of RB1CC1 suppressed them (Fig. 2D). These promoter enhancements by RB1CC1 were compared among HeLa, TTY652 (hSNF5-null) and H1299 (p53-null) cells, in order to validate the requirement for hSNF5 or p53 when RB1CC1 activates RB1, p16 and p21. RB1CC1 was unable to provide significant enhancement of RB1 and p16 promoters in TTY652 cells, and played only a small role in p16 and p21 transcription in H1299 cells (Fig. 2E). Considering the RB1 pathway initiated by RB1CC1, RB1CC1 requires hSNF5 for enhancement of RB1 and p53 for enhancement of p21 transcriptions, but both hSNF5 and p53 are needed for RB1CC1 enhancement of p16 transcription. In summary, RB1CC1 requires interaction with both hSNF5 and p53 to provide a strong activation of RB1, p16 and p21 promoters.

RB1CC1 activates the RB1 pathway and suppresses tumor growth

To evaluate whether RB1CC1 enhances RB1 pathways to suppress cancer cell growth, HeLa cells were lentivirally transduced with RB1CC1 cDNA or shRNA. Ectopic expression of RB1CC1 increased the protein levels of p53, p21, p16 and RB1, and inhibited the cell growth (Fig. 3A and B, left panel). In contrast, the knockdown of endogenous RB1CC1 by sh-RB1CC1 decreased the levels of p53, hSNF5, p21 and p16, and enhanced the cell growth (Fig. 3A and B, right panel). The same experiments in two breast cancer cell lines (MCF-7 and SK-BR3) yielded similar results (Fig. S2A-D). In RB1CC1-transduced cells, the number of G0/G1-phase-cells was increased concomitantly with the decrease of the numbers of cells in S and G2/M phases. Introduction of sh-RB1CC1 decreased the G0/G1 population and increased the populations of cells in S and G2/M (Fig. 3C; Fig S2E).

Taken together, the above-mentioned data indicated that RB1CC1 formed a complex with hSNF5 and/or p53, and globally activated the transcription of RB1, p16 and p21 (Fig. 3D).

Expressional analysis of the molecules involved in the RB1CC1-RB1 pathway in breast cancers in vivo

To evaluate the correlation between the proliferative activity and the above-mentioned RB1CC1 pathway of RB1 activation involving p53 and hSNF5 in tumor tissue in vivo, we evaluated the expressional status of RB1CC1, RB1, p16, p21, Ki-67, p53 and hSNF5 in 59 cases of breast cancer. Four cases of RB1 nullizygotes indicated a high Ki-67 proliferation index (means ± standard errors = 69.7±6.6%). The immunoreactivity of p53—referring to p21 expression—was divided into two categories, “normal” (p53nor) for weak staining and “abnormal” (p53ab) for strong staining, which highly indicated that mutant p53 protein was accumulated. There were 41 and 14 cases of p53nor and p53ab, respectively, in this series. hSNF5 was highly maintained in breast cancers, irrespective of RB1CC1 or p53 status (data not shown). The immunohistochemical results for RB1CC1 were quantitatively graded as I-III. Grade III, expressing RB1CC1 abundantly in cell nuclei, was recorded as RB1CC1 (+), whereas grades I-II without nuclear RB1CC1 were recorded as (−) (Fig. 4A). As reported previously [4], the expression of RB1 was quite well correlated with RB1CC1 expression in the cases recorded as RB1CC1 (+) and was higher than in the RB1CC1 (−) cases (Fig. 4B, left). p16 expression was also correlated positively with nuclear RB1CC1 expression (Fig. 4B, 3rd left and right). Together, the expression status of RB1CC1 and p53 were associated with increased expressions of RB1, p16 and p21, which in turn influenced the Ki-67 index of proliferation activity in clinical breast cancers. Therefore, the immunohistochemical status of RB1 and p53 as well as that of RB1CC1 should be good predictors of the proliferative activity; thus, the RB1CC1-RB1 pathway demonstrated in our experiments could play a significant role in the progression of clinical breast cancer.

Discussion

RB1CC1 is a novel regulator of RB1 that dephosphorylates RB1 [2,6] and increases its expression [2,4]; in addition, a genetic rearrangement of RB1CC1 might be involved in breast cancer tumorigenesis [3,5]. More recently, we reported that nuclear RB1CC1 directly activates the RB1 promoter through a 201bp upstream GC-rich region (−201/U-GCbox) [4]. To clarify more precisely the molecular mechanism of the RB1CC1 action, an immunoprecipitation assay followed by LC-MS/MS was attempted, and a chromatin remodeling factor, hSNF5 was identified. RB1CC1 also interacts with p53, so RB1CC1 is thought to form a complex with hSNF5 and/or p53. It is thought that RB1CC1 induces RB1 [2,4], and that hSNF5 enhances p21 (also known as INK4a or CDKN2A) and/or p27 (also known as CIP1, WAF1 or CDKN1A) [7,8,9,10]. In fact, immunoprecipitation and immunofluorescence assays have indicated that a complex between RB1CC1, hSNF5 and p53 forms in cell nuclei, and ChIP, quantitative RT-PCR and the luciferase assays for RB1, p16 and p21 have suggested that the coordinated transcriptional enhancement-
RB1CC1 Activates RB1 Pathway

A

B

C

D

E

Luciferase activity

RB1

p16

p21
ments of these molecules are affected by the complex including RB1CC1, hSNF5 and p53. However, RB1CC1, hSNF5 and p53 are not equally important to the stimulation of each of the promoters of RB1, p16 or p21, while three molecules are recruited to each promoter. For example, silencing p53 in HeLa cells had no effect on the transcription of RB1, and RB1CC1 over-expression can activate the RB1 promoter in H1299 (p53-null) cells. These mean that p53 isn’t essentially required to RB1 transcription, and that RB1CC1 and hSNF5 can co-operate to activate RB1 transcription. Thus, all three molecules are not always required for activation of each of the promoters, while all three are needed for the coordinated transcriptions of RB1, p16 and p21. We have also established earlier that nuclear RB1CC1 binds to and activates the RB1 promoter [4]. Interestingly, a point-mutation in the −201/U-GCbox of the RB1 promoter was identified in a hereditary retinoblastoma family [11]. It should be pointed out that the −201/U-GCbox of RB1 and the binding transcriptional complex that includes RB1CC1, hSNF5 and p53 play important roles in human carcinogenesis.

In the present study, RB1CC1, in collaboration with hSNF5 and p53, activates the RB1 pathway and suppresses tumor cell growth. In order to activate the RB1 pathway effectively, RB1CC1 must be expressed in cell nuclei and should form a complex with hSNF5 and/or p53, as suggested in the immunocytochemical and immunohistochemical data of this study. PIASy (a protein-inhibitor of activated STAT protein y) interacts with the C-terminus (aa 1350–1594) of RB1CC1 and recruits an interacting complex between PIASy and RB1CC1 from cytoplasm into nuclei [12]. In addition, PIASy negatively regulates mammalian target of rapamycin (mTOR) activity stimulated by cytoplasmic RB1CC1, and positively activates the p53-p21 signaling pathway together with nuclear RB1CC1 [12]. These data seem to be compatible with our presented data on the sublocalization of the complex composed of RB1CC1, hSNF5 and p53. The nuclear molecular complex, including RB1CC1, hSNF5, p53 and additional PIASy, can form a large transcriptional component to activate the RB1 pathway coordinately and repress the tumorigenesis in human breast tissue.

Nuclear expression of RB1CC1 could be important for tumor suppression. As reported previously, RB1CC1 is located not only in the nucleus but also in the cytoplasm [4,6,13,14]. Cytoplasmic RB1CC1 has been suggested to be the equivalent of yeast Atr17, and several studies have indicated that RB1CC1 functions as an essential molecule in autophagy regulation [13,14,15]. Autophagy has been implicated in tumorigenesis, but its precise role is ambiguous. It is conceivable that autophagy has different roles in apoptosis-senescence association. Our data in vivo and in vitro suggest that RB1CC1 plays different roles according to its subcellular location. Nuclear RB1CC1 forms a complex with hSNF5, p53 and any other component that contributes to the transcription of the RB1 pathway, indicating a possible linkage to mitotic senescence. However, cytoplasmic RB1CC1 seems to play no role as a tumor suppressor activating the RB1 pathway.

Nuclear RB1CC1 expression significantly correlated with those of RB1 and p16 in breast cancer tissue in vivo, irrespective of p53 status. Ki-67 proliferation index and p21 expression were affected by both RB1CC1 and p53, and the Ki-67 index also depended on RB1 status. The expressions of RB1, p16 and p21 affect the Ki-67 index of proliferative activity, so the immunohistochemical status of RB1 and p53 as well as that of RB1CC1 can predict the proliferative activity of the tumor. Thus, the present data suggested that progression of the breast cancers was under the strong influence of RB1CC1, as well as RB1 and p53 status. We expect that the combined immunohistochemical evaluation of RB1, RB1CC1 and p53 will provide insight into their clinical applications, such as possible use as prognostic biomarkers.

In summary, we have reported here that RB1CC1, connecting the RB1 and p53 pathways as a possible mediator, forms a complex with hSNF5 and/or p53 that enhances the RB1 pathway globally. Immunohistochemical evaluation of RB1 and p53 in combination with RB1CC1 may be a useful biomarker in convenient, routine clinical assays and provide a prediction of the biological behavior of breast neoplasms and/or the tumors of other organs.

Materials and Methods

Cell culture

TTC642 was kindly provided by Drs. Shigeru Ohta, Hiroyuki Shimada and Timothy J. Triche (Children’s Hospital Los Angeles, Los Angeles, CA). HeLa, HEK293, MCF-7, SK-BR3 and H1299 cells were purchased from American Type Culture Collection (MD), and cultured in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 containing 10% fetal bovine serum. All cell culture media were supplemented with penicillin (50 units/ml) and streptomycin (50 mg/ml).

Antibodies and reagents

Rabbit antisera against RB1CC1 (aa. 25–271, 549–817 as each epitope) were generated as previously reported [4,17], and the purified IgG were used in the experiments. Anti-p53 (FL-393) and anti-p21 (F-5) were obtained from Santa Cruz Biotechnology (CA). Anti-HA (3F10) was from Roche (Germany). Anti-Flag (M2) and anti-tubulin z (DM 1A) were purchased from Sigma (MO). The other antibodies were from BD Biosciences (CA).
Figure 3. RB1CC1 activates the RB1 pathway and suppresses tumor growth. (A) HeLa cells were lentivirally transduced with RB1CC1 or sh-RB1CC1. Lysates were immunoblotted as indicated. (B) Growth assays in HeLa cells transduced as in a. The data were quantified from triplicate experiments (lower column). Representative immunoblots, plates and mean colony numbers ± standard errors are shown. (C) After the lentiviral modification of RB1CC1 expression, NIH3T3 cells were analyzed by flow-cytometry. RB1CC1 and sh-RB1CC1 are indicated by red (left) and blue (right), respectively. The data (mean percentages ± standard deviations) were confirmed in triplicate experiments, and a representative flow cytometric graph is demonstrated. pLenti6 and sh-GL3 were used as controls. Arrows indicate that increases (up-arrow) and decreases (down-arrow) were statistically significant according to the Student’s t-test; p<0.05 (D) RB1CC1, hSNF5 and p53 form the transcriptional complex in cell nuclei, and activate RB1, p16 and p21.

doi:10.1371/journal.pone.0011404.g003
Immunoprecipitation of protein complex followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

The MCF-7 breast cancer cells were lysed in EBC lysis buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40 (NP-40), 0.25% sodium deoxycholate, 0.2 mM Na_3VO_4, 100 mM NaF and 1% protease inhibitor cocktail (Wako Chemicals, Japan), and then centrifuged for 20 min at 20,000 x g at 4°C. The 5 ml supernatant (~10 mg/ml) was incubated with 100 μg of anti-RB1CC1 purified IgG primary antibody at 4°C overnight. The immunocomplexes were bound to protein G-agarose (Pierce, IL) for additional 2 h at 4°C and washed five times with NETN (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40). The proteins bound to the protein G-Sepharose were eluted by adding Laemmli SDS

Figure 4. In vivo significance of RB1CC1. (A) The immunohistochemical grades of RB1CC1 were classified as I-III: I, negative stain in both cytoplasm and nuclei; II, positive stain only in cytoplasm and negative in nuclei; III, positive stain in nuclei and/or cytoplasm. Grades III, expressing RB1CC1 abundantly in cell nuclei, were recorded as RB1CC1 (+), whereas grades I-II without nuclear RB1CC1 were recorded as RB1CC1 (−). Scale bar shows 50 μm. (B) Correlation between RB1CC1 and RB1, p16, p21 or Ki-67 in p53 normal (upper graphs) and abnormal (lower graphs) cases. RB1CC1 (−) or (+) status is indicated on the horizontal line, and each labeling index is indicated on a vertical line in the graphs. An abnormal p53 status was defined as a case of breast cancer when more than 50% of the tumor cells were strongly positive for p53, while less than 10% of the cells were positive for p21. Such case highly indicated that mutant p53 protein was accumulated, and that the intact functions of p53 (like transcriptional activation for p21) were loss. Student’s t-test was used to evaluate the correlations (*, p<0.05; and **, p<0.01).

doi:10.1371/journal.pone.0011404.g004
sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 10% glycerol, 5% 2-mercaptoethanol, 2% SDS, and 0.01% bromophenol blue to the gel and boiling for 3 min. After centrifugation at 10,000 × g for 2 min, the supernatant was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were visualized by silver staining. The strongly stained specific band was in-gel digested with trypsin, and the recovered peptides were analyzed using an electrospray ion-trap mass spectrometer (LCQ, Finnigan MAT, CA) coupled online with capillary HPLC (Magic 2002, Microm BioResources, CA) to acquire mass spectrometry/mass spectrometry (MS/MS) spectra. Data derived from the MS/MS spectra were used to search a compiled protein database, which was composed of database NR and a six-reading-frame translated EST database, to identify the protein by using the publicly available program PROWL (http://prowl.rocket流水.edu).

Plasmid DNA and gene transfer

External and internal deletion mutants for RB1CC1 (GenBank no. NM_014781) were generated in the pcDNA3.1 plasmid vector (Invitrogen), by a combination of PCR-based manipulations with appropriate external primers at the positions described below and restriction enzyme digestion. The nucleotides of all constructs were confirmed by DNA sequencing. The vectors were prepared with each packaging mix, according to each manufacturer’s instructions. Cloned and expanded cells were selected in the presence of puromycin or blasticidin, respectively, and used in the experiments.

Pull-down assay

Flag-tagged-wildtype (wt) RB1CC1 or its mutants (dCC, dCB, dLZ, dLC, dCC and Fcc) were transfected into HEK293 cells using 10,000–13,600, 13,600–15,940, 1–13,560, 8,240–15,940 and 1–8,630, respectively. Transfection was performed using FuGENE HD (Roche) according to the supplier’s recommendations. Plasmid vectors for RNAi for RB1CC1 were prepared as described previously [17]. Briefly, two kinds of lentiviral sh-RNA vectors (sh-RB1CC1-1 and -2) corresponding to different target sites (nt. 2,070–2,090 and nt. 4611–4631, respectively) on RB1CC1 mRNA (GenBank no. NM_014781) were synthesized in vitro by inserting artificial oligonucleotides into the pSH1-H1-Puro shRNA vector (System Biosciences, CA). Vectors for sh-RNA of hSNF5 and p53 were prepared by OpenBiosystems (AL). For non-silencing controls, sh-GLS and scramble vectors were purchased from System Biosciences and OpenBiosystems, respectively. Additionally, human RB1CC1 cDNA was subcloned into a pLenti6 vector (Invitrogen). Lentivirus transferring sh-RNA or cDNA was prepared with each packaging mix, according to each manufacturer’s instructions. Cloned and expanded cells were selected in the presence of puromycin or blasticidin, respectively, and used in the experiments.

Immunofluorescence assay

MCF-7 and HeLa cells were cultured on LabTekTM chamber slides (BD Biosciences) to 70% confluence, fixed with 1% buffered formaldehyde and 70% ethanol, and then permeabilized with 0.1% Triton X-100. The primary antibody rabbit anti-RB1CC1 IgG, mouse anti-hSNF5 IgG2a (BAF48), and rabbit anti-p53 IgG (FL393) were conjugated with Alexa 488, 594 and 350 by the ZenonTM labeling kit (Molecular Probes). To evaluate the subcellular location, 4',6-diamidino-2-phenylindole (DAPI) was also applied in HeLa and MCF-7 cells. The labeled primary antibodies were incubated overnight at 4°C. The slides were then washed in TBS-T and incubated for 1 h in horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-rat IgG (GE Healthcare, UK) diluted 1:20,000 in TBS-T containing 2% BSA. After several washes with TBS-T, the immunoreactivity was detected using the ECL system (GE Healthcare) according to the procedures recommended by the manufacturer.

Chromatin immunoprecipitation (ChIP) assay

For ChIP of the endogenous RB1, p21 and p16 promoter regions in HeLa cells, the ChIP-IT™ control kit and ChIP-IT™ Express (Active Motif, CA) were used, and the assay performed essentially as described in the Active Motif protocol. The used antibodies were anti-RB1CC1, anti-hSNF5 (BAF48), anti-p53 (FL393) and control rabbit IgG (Active Motif). The immunoprecipitated DNA was quantified by the quantitative (Real-time) and semi-quantitative polymerase chain reaction. The amplified promoter regions of RB1 and p16 were from –385 to –110, and from –712 to –529, respectively (the first ATG was defined as +1). For the p21 promoter, the region from –2432 to –2175 (the transcriptional start site was defined as +1) was amplified. The sequences of the PCR primers and suitable PCR conditions are available upon request.

Immunoprecipitation to detect the protein complex

MCF-7 monolayer cells were rinsed with ice-cold phosphate-buffered saline (PBS) and scraped into ice-cold NP-40 lysis buffer (20 mmol/L Tris (pH 8.0), 137 mmol/L NaCl, 1% NP-40, 10% glycerol) supplemented with 1% protease inhibitor cocktail (Wako Chemicals) and 3 mmol/L Na3VO4. Lysates were incubated on ice for 20 minutes, cleared by centrifugation, and protein concentration was determined by the bicinchoninic acid assay (Pierce). Solutions containing 400 to 1,000 μg of protein were briefly precleared with protein-G-agarose beads (Pierce) and then used for the immunoprecipitation reaction with 2 kinds of anti-RB1CC1 rabbit polyclonal IgGs or normal control rabbit IgGs at 4°C overnight, followed by incubation with protein-G beads for 2 hours to collect immune complexes. Finally, the beads were washed with NP-40 buffer five times, resuspended in SDS sample buffer, boiled, resolved on SDS-PAGE, and analyzed by immunoblots as described below.
Reverse transcription-polymerase chain reaction (RT-PCR) in the specifically knocked-down cells for RB1CC1, hSNF5 or p53

Transcriptional expressions of RB1, p21 and p16 were evaluated by the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method between sh-GL3 control and the genespecific knocked-down HeLa cells, transfected lentivirally with shRNA for RB1CC1 (sh-RB1CC1), hSNF5 (sh-hSNF5) and p53 (sh-p53). Transcribed mRNA in each knocked-down cell was adequately quantified by semi-quantitative RT-PCR at the individual cycle number for each transcript. The sequences of the PCR primers and suitable RT-PCR conditions are available upon request.

Luciferase-reporter assay

HeLa, TTC642 (hSNF5-null) and H1299 (p53-null) cells were seeded at 0.7×10⁵ cells/well in 6-well plates. On the next day, RB1-, p21- or p16-luciferase reporter plasmid was cotransfected by FuGENE HD (Roche) with plasmids empty vector and/or RB1CC1-cDNA, -shRNA vector. Twenty-four hours later, cells were lysed, and luciferase activity was analyzed using a Luciferase assay kit (Toyo Ink, Japan) and luminometer (EG&G Berthold). Transcribed mRNA in each knocked-down cell was appropriately amplified by semi-quantitative RT-PCR at the individual cycle number for each transcript. The sequences of the PCR primers and suitable RT-PCR conditions are available upon request.

Cell cycle analysis

To analyze the cell cycle between pLenti6 control and RB1CC1-expression; sh-GL3 control and RB1CC1-knockdown cells, the distribution of DNA content was measured using the CycleTEST™ PLUS kit (Becton Dickinson). Flow cytometric data were collected on a FACSCaliber, and analyzed with CellQuest software.

Cell growth assay

The cells were prepared at 1×10⁵ cells/well in 6-well plates, lentivirally transduced with cDNA or shRNA for RB1CC1, and incubated in the presence of blasticidin or puromycin, respectively. After 10–20 days of transduction, the cells were fixed with 10% acetate/10% methanol for 20 minutes, and stained with 0.4% crystal violet in 20% ethanol for 15 minutes to visualize the colonies.

Patients and histology

A total of 72 consecutive patients with operable primary breast cancers, treated in Shiga University of Medical Science or in Osaka Medical Center for Cancer and Cardiovascular Diseases around 1999, were studied. Among these, we failed to assess the immunohistochemical evaluations in 13 tumor specimens as a result of tissue loss during slide preparation. Therefore, specimens from 59 patients with primary breast cancer were analyzed in this study. They were collected with the written informed consent of patients, and after approval by the Ethics Committee of Shiga University of Medical Science. The pathological diagnoses of all patients were confirmed in 3 categories: I, negative stain in both cytoplasm and nuclei; II, positive stain only in cytoplasm and negative in nuclei; III, positive stain in nuclei and/or cytoplasm. However, our recent study proved that RB1 expression was significantly higher in the cases with nuclear RB1CC1 expression (grade III) than in the cases without nuclear RB1CC1 (grade I and II) [4]. Therefore, RB1CC1 staining grades I-II and III were defined as -negative (−) and -positive (+), respectively. A dysfunctional status of p53 was assessed immunohistochemically by the percentage of cells that were positive for p53 and p21. An abnormal p53 status (p53ab) was defined as a case of breast cancer when more than 50% of tumor cells were strongly positive for p53, while less than 10% of the cells were positive for p21. Nuclear expressions of p16 and p21 in tumor cells were recognized as positive labels.

Statistical analysis of difference between RB1CC1 and the other indicators

Student’s t-test was used to evaluate the relationships between RB1CC1 staining and the labeling indices of RB1, p16, p21 and Ki-67. A p-value of <0.05 was considered statistically significant.

Supporting Information

Figure S1 RB1CC1 interacts with hSNF5 and p53 mainly in cell nuclei. (A) RB1CC1 (green), hSNF5 (red), p53 (blue) and the merged image in MCF-7 cells. Each protein is immunofluorescently labeled by Alexa 488, 594 or 350 respectively. Scale bar, 50 μm. (B) RB1CC1 (green), DAPI and the merged image are displayed with blue fluorescence in cell nuclei. Scale bar, 50 μm. Found at: doi:10.1371/journal.pone.0011404.s001 (0.90 MB TIF)

Figure S2 Modulation of RB1CC1 affects the growth of breast cancer cells through RB1, p21 and/or p16 expression. (A) In MCF-7 breast cancer cells, RB1CC1 induced RB1, p53 and p21 expression, and, conversely, the knockdown (sh-RB1CC1) reduced their expression. (B) RB1CC1 suppressed and sh-RB1CC1 enhanced the cell growth of MCF-7. (C) In SK-BR3 breast cancer cells, RB1CC1 induced RB1, hSNF5, p16 and p21 expression. sh-RB1CC1 decreased the p16 and p21 contents. (D) RB1CC1 suppressed and sh-RB1CC1 enhanced the cell growth of SK-BR3. A and C indicate the Western blots data. B and D show the results of cell growth assays. Modulation was performed by lentiviral transduction of cDNA or sh-RNA of RB1CC1 into the cells. pLenti6 and sh-GL3 were used as controls. The experiments were performed in triplicate. Representative immunoblots, plates and mean colony numbers ± standard errors are shown. (E) After the lentiviral modification of RB1CC1 expression, HeLa cells were analyzed by flow cytometry. RB1CC1 and sh-RB1CC1 are indicated by red (left) and blue (right), respectively. The data (mean percentages ± standard deviations) were confirmed in
triplicate experiments, and a representative flow cytometric graph is demonstrated. Arrows indicate whether statistically significant increases (up-arrow) or decreases (down-arrow) are present according to the Student’s t-test; p<0.05.

**Table S1** The primer sequences and conditions for ChIP-PCR and RT-PCR.

**References**

1. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25: 5220–5227.
2. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, et al. (2002) Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 21: 1293–1298.
3. Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S (2002) Truncating mutations of RB1CC1 in human breast cancer. Nat Genet 31: 285–288.
4. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shima T, et al. (2009) RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 125: 861–867.
5. Schmidt-Kinlter O, Ragg T, Daskalakis A, Granarov M, Ahr A, et al. (2003) From latent disseminated cells to overt metastatic: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100: 7737–7742.
6. Melkoumian ZK, Peng X, Gan B, Wu X, Guan JL (2005) Mechanism of cell cycle regulation by FIP200 in human breast cancer cells. Cancer Res 65: 6676–6684.
7. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE (2002) Re-expression of bSNF5/INi1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16Ink4a and activation of RB. Oncogene 21: 5193–5203.
8. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, et al. (2002) SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 277: 22330–22337.
9. Chai J, Charbonneau AL, Betz BL, Weissman BE (2005) Loss of the bSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65: 10192–10198.
10. Greish L, Bourachot B, Reimann A, Guigas B, Fiette L, et al. (2005) The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. Embryog J 24: 3313–3324.
11. Sakai T, Ohtani N, McGuire TI, Robbins PD, Dryja TP (1999) Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 353: 83–86.
12. Martin N, Schwamborn K, Urlaub H, Gan B, Guan JL, et al. (2008) Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity. Mol Cell Biol 28: 2771–2781.
13. Hara T, Takamura A, Kishi G, Inamura S, Natsume T, et al. (2008) FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol 181: 497–510.
14. Hosokawa N, Hara T, Kaizuka T, Kishi G, Takamura A, et al. (2009) Nutrient-dependent mTORC1 Association with the ULK1-Atg13-FIP200 Complex Required for Autophagy. Mol Biol Cell 20: 1981–1991.
15. Hara T, Mizushima N (2009) Role of ULK-FIP200 complex in mammalian autophagy: FIP200, a counterpart of yeast Atg17? Autophagy 5: 85–87.
16. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. (2009) Autophagy mediates the mitotic senescence transition. Genes Dev 23: 798–803.
17. Chano T, Saji M, Inoue H, Minami K, Kobayashi T, et al. (2006) Neuromuscular abundance of RB1CC1 contributes to the non-proliferating enlarged cell phenotype through both RB1 maintenance and TSC1 degradation. Int J Mol Med 18: 425–432.
18. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
19. Yagi A, Hasagawa Y, Xiao H, Haneda M, Kojima E, et al. (2003) GADD34 induces p53 phosphorylation and p21/WAF1 transcription. J Cell Biochem 90: 1242–1249.

**Acknowledgments**

We are grateful to Masashi Saji, Hiroko Kita and Sawako Hirayama for experimental assistance.

**Author Contributions**

Conceived and designed the experiments: TC HO. Performed the experiments: TC KI YO HT IN KM TI. Analyzed the data: TC KI YO HT YJ HI MI KT HI TI MS TS YH. Wrote the paper: TC KI HO.